![Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-](https://static.cymitquimica.com/products/AN/img/AG000I9P.png "Clique para ampliar")
Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-
CAS: 119169-78-7
Ref. AN-AG000I9P
| 1mg | 160,00 € | ||
| 2mg | 239,00 € | ||
| 5mg | 510,00 € | ||
| 10mg | 600,00 € | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Entrega estimada em Estados Unidos, Terça-feira 11 de Junho de 2024
Informação sobre produto
Nome:
Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-
Sinónimos:
- 17-N-t-butylcarboxamide androst-3,5-diene-3-carboxylic acid
- epristeride
- Epristeride
- 17-beta-N-t-Butylcarboxamide-androst-3,5-diene-3-carboxylic acid
- 17beta-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
- (17-beta)-17-(((1,1-Dimethylethyl)amino)carbonyl)androsta-3,5-diene-3-carboxylic acid
- Androsta-3,5-diene-3-carboxylic acid, 17-(((1,1-dimethylethyl)amino)carbonyl)-, (17beta)-
- (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- 17-tert-Butylcarbamoyl-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17beta)-
- Ver mais sinónimos
- Androsta-3,5-diene-3-carboxylicacid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17b)-
- (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- 17-N-t-butylcarboxamide androst-3,5-diene-3-carboxylic acid
- 17beta-(N-t-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
- (10R,13S)-17-tert-Butylcarbamoyl-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- (10R,13S,17S)-17-tert-Butylcarbamoyl-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- (10R,14S)-17-tert-Butylcarbamoyl-10-methyl-13-(S)-methyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- Androsta-3,5-diene-3-carboxylic acid, 17-(((1,1-dimethylethyl)amino)carbonyl)-, (17-beta)-
- Zariflo
- 17b-(n-tert-butylcarboxamido)androsta-3,5-diene-3-carboxylic acid
- (10R,13S,17S)-17-Diisopropylcarbamoyl-10,13-dimethyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid
- (17b)-17-[[(1,1-Dimethylethyl)amino]carbonyl]androsta-3,5-diene-3-carboxylic Acid
- (17beta)-17-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
- 119169-78-7
- 17-(Tert-Butylcarbamoyl)Androsta-3,5-Diene-3-Carboxylic Acid
- 17β-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid
- Androsta-3,5-Diene-3-Carboxylic Acid, 17-[[(1,1-Dimethylethyl)Amino]Carbonyl]-, (17Beta)-
- N-tert-Butylandrosta-3,5-diene-17β-carboxamide-3-carboxylic acid
- Ono 9302
- Skf 105657
CAS:
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Indagoo
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
399.5662
Fórmula:
C25H37NO3
Pureza:
≥99%
InChI:
InChI=1S/C25H37NO3/c1-23(2,3)26-21(27)20-9-8-18-17-7-6-16-14-15(22(28)29)10-12-24(16,4)19(17)11-13-25(18,20)5/h6,14,17-20H,7-13H2,1-5H3,(H,26,27)(H,28,29)/t17-,18-,19-,20+,24-,25-/m0/s1
Chave InChI:
VAPSMQAHNAZRKC-PQWRYPMOSA-N
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
Consulta técnica sobre: AN-AG000I9P Androsta-3,5-diene-3-carboxylic acid, 17-[[(1,1-dimethylethyl)amino]carbonyl]-, (17β)-
Por favor, utilize o carrinho para solicitar um orçamento ou uma encomenda
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
